Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,700 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 6 April 2021) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download:

 (PDF, 5MB, 226 pages) 

This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website

 

 

Export 9 results:
Author Title Type [ Year(Asc)]
Filters: Author is Emsley, R.  [Clear All Filters]
2020
A. K. Wright, Welsh, P., Gill, J. M. R., Kontopantelis, E., Emsley, R., Buchan, I., Ashcroft, D. M., Rutter, M. K., and Sattar, N., Age-, sex- and ethnicity-related differences in body weight, blood pressure, HbA(1c) and lipid levels at the diagnosis of type 2 diabetes relative to people without diabetes, Diabetologia, 2020.
A. Pate, Van Staa, T., and Emsley, R., An assessment of the potential miscalibration of cardiovascular disease risk predictions caused by a secular trend in cardiovascular disease in England, BMC Med Res Methodol, vol. 20, p. 289, 2020.
A. Pate, Emsley, R., and Van Staa, T., Impact of lowering the risk threshold for statin treatment on statin prescribing: a descriptive study in English primary care, Br J Gen Pract, vol. 70, pp. e765-e771, 2020.
A. Pate, Emsley, R., Sperrin, M., Martin, G. P., and Van Staa, T., Impact of sample size on the stability of risk scores from clinical prediction models: a case study in cardiovascular disease, Diagn Progn Res, vol. 4, p. 14, 2020.
A. Pate, Elliott, R. A., Gkountouras, G., Thompson, A., Emsley, R., and Van Staa, T., The impact of statin discontinuation and restarting rates on the optimal time to initiate statins and on the number of cardiovascular events prevented, Pharmacoepidemiol Drug Saf, 2020.
A. K. Wright, Suarez-Ortegon, M. F., Read, S. H., Kontopantelis, E., Buchan, I., Emsley, R., Sattar, N., Ashcroft, D. M., Wild, S. H., and Rutter, M. K., Risk Factor Control and Cardiovascular Event Risk in People With Type 2 Diabetes in Primary and Secondary Prevention Settings, Circulation, vol. 142, pp. 1925-1936, 2020.
[Page last reviewed 6 April 2021]